- Home
- ALEC vs FATE Comparison
ALEC vs FATE Comparison
Compare ALEC & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALEC | FATE |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.2M | 131.5M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ALEC | FATE |
|---|---|---|
| Price | $1.50 | $1.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $3.50 | ★ $3.92 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,048,000.00 | $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $160.66 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.26 | N/A |
| 52 Week Low | $0.87 | $0.66 |
| 52 Week High | $3.40 | $2.22 |
Technical Indicators
Market Signals| Indicator | ALEC | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 54.23 |
| Support Level | $1.18 | $1.03 |
| Resistance Level | $1.39 | $1.16 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 91.11 | 94.20 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.